Seeking Alpha

Moderna +16% on positive CMV vaccine data

|About: Moderna, Inc. (MRNA)|By:, SA News Editor

Clinical-stage biotech Moderna (NASDAQ:MRNA) has gained 16% on heavy postmarket volume after it posted postive Phase 1 data for its Cytomegalovirus vaccine mRNA-1647.

That comes after the third and final vaccination with the investigational treatment in Phase 1.

It also says the first participant was dosed in the Phase 2 dose-confirmation study.

The company says it's actively preparing for a Phase 3 pivotal study to evaluate efficacy of mRNA-1647 against primary CMV infection.

It will discuss the data in a conference call tomorrow at 8 a.m. ET.

Try Seeking Alpha PREMIUM for unlimited analysis on MRNA